13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001792126
Total reported value
$2.3B
$2.3B
53 檔
20.0%
During the Q1 2024 filing period, Logos Global Management LP (CIK: 0001792126) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.3B across 53 reported positions.
During Q1 2024, Logos Global Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 16.76% | — | +128.57% | |
| 2 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 6.05% | — | — | |
| 3 | IDYA | Ideaya Biosciences Inc | Stock-Other | 5.33% | -0.93% | -16.67% | |
| 4 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 4.73% | -1.44% | +125.00% | |
| 5 | IMVT | Immunovant Inc | Stock-Other | 4.64% | -0.23% | +47.92% | |
| 6 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.21% | +0.61% | +45.29% | |
| 7 | GPCR | Structure Therapeutics Inc | Stock-Other | 4.06% | -0.04% | +9.35% | |
| 8 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 4.02% | -0.66% | — | |
| 9 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.98% | +1.17% | -7.98% | |
| 10 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.81% | — | -58.97% | |
| 11 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 2.83% | — | +1.96% | |
| 12 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.56% | — | +311.95% | |
| 13 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.52% | — | +269.02% | |
| 14 | GERN | Geron CORP | Stock-Other | 2.40% | — | — | |
| 15 | ANNX | Annexon Inc | Stock-Other | 2.35% | +0.37% | NEW | |
| 16 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.21% | +2.65% | — | |
| 17 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.14% | -1.02% | +412.65% | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 2.01% | +4.06% | NEW | |
| 19 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 1.72% | — | — | |
| 20 | DSGN | Design Therapeutics Inc | Stock-Other | 1.64% | +0.83% | — | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.64% | — | — | |
| 22 | CYBNEUR | Cybin Inc | Stock-Other | 1.34% | — | — | |
| 23 | XNCR | Xencor Inc | Stock-Other | 1.16% | — | — | |
| 24 | CGON | Cg Oncology Inc | Stock-Other | 1.07% | +1.12% | — | |
| 25 | ✓ | Engene Holdings Inc | Stock-Other | 1.04% | — | — | |
| 26 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.01% | — | — | |
| 27 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.99% | — | +16.67% | |
| 28 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.97% | — | — | |
| 29 | ✓ | Immatics NV | Stock-Other | 0.85% | — | — | |
| 30 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.77% | — | +66.67% | |
| 31 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.76% | — | -16.67% | |
| 32 | LCTX | Lineage Cell Therapeutics In | Stock-Other | 0.75% | — | — | |
| 33 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.74% | -0.83% | — | |
| 34 | APLT | Applied Therapeutics Inc | Stock-Other | 0.73% | — | -18.67% | |
| 35 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.67% | — | — | |
| 36 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.61% | +0.08% | — | |
| 37 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.57% | -2.88% | EXIT | |
| 38 | KURA | Kura Oncology Inc | Stock-Other | 0.52% | — | — | |
| 39 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 40 | ATYR | Atyr Pharma Inc | Stock-Other | 0.49% | — | -47.01% | |
| 41 | JANX | Janux Therapeutics Inc | Stock-Other | 0.46% | -0.69% | EXIT | |
| 42 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.43% | — | — | |
| 43 | ✓ | Elevation Oncology Inc | Stock-Other | 0.42% | — | — | |
| 44 | NXTCEUR | Nextcure Inc | Stock-Other | 0.35% | — | — | |
| 45 | ALLKGUSD | Allakos Inc | Stock-Other | 0.30% | — | — | |
| 46 | ✓ | Stock-Other | 0.24% | — | — | ||
| 47 | BOLD | Boundless Bio Inc | Stock-Other | 0.23% | — | — | |
| 48 | TRML | Tourmaline Bio Inc | Stock-Other | 0.18% | — | -65.11% | |
| 49 | CMPS | Compass Pathways PLC | Stock-Other | 0.15% | +1.37% | NEW | |
| 50 | IOBTQ | Io Biotech Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, Logos Global Management LP reported a total U.S. public equity portfolio value of $2.3B across 53 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SRPT, ALNY, IDYA) accounted for 20.0% of total reported equity market value during Q1 2024.
During Q1 2024, Logos Global Management LP's top holdings by market value included SRPT (16.8%)、ALNY (6.0%)、IDYA (5.3%). The largest single position, SRPT, represented 16.8% of total portfolio value.
In Q1 2024, Logos Global Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.